Complicated Skin and Skin Structure Infections Drugs Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The complicated skin and skin structure infections drugs market size has grown rapidly in recent years. It will grow from $9.51 billion in 2024 to $10.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $15.2 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

The increasing prevalence of skin diseases is anticipated to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Skin diseases are medical conditions impacting the skin's appearance, structure, and function and may involve the skin, hair, nails, and related tissues. A variety of antibiotic drugs are utilized to treat resistant bacteria in cSSSI cases. Therefore, the rise in skin disease incidence can lead to new cSSSI drug approvals, increase awareness, and promote early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that the average number of new melanoma skin cancer cases each year in the UK is projected to increase from around 20,800 cases in 2023-2025 to approximately 26,500 cases in 2038-2040. This marks a projected 9% rise in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Thus, the growing prevalence of skin disease is fueling the expansion of the cSSSI drugs market.

Rising healthcare expenditure is expected to further drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Healthcare expenditure refers to the total spending on healthcare services, related goods, and activities within a specific healthcare system or economy over a given period. Higher healthcare costs are a significant factor for complex skin and skin structure infection medications, not only enhancing access to healthcare services but also supporting the research, development, and distribution of cSSSI medications. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based federal agency, projected in the 2021-2030 National Health Expenditure (NHE) report that national health spending would grow at an average annual rate of 5.1% from 2021 to 2030, reaching nearly $6.8 trillion. Additionally, Medicare spending is anticipated to increase at a 7.2% annual rate, while Medicaid spending is projected to grow by 5.6% annually during the same period. Thus, rising healthcare expenditures are bolstering the growth of the cSSSI drugs market.

To maintain their competitive positions in the complicated skin and skin structure infections drugs market, major companies are committed to developing cutting-edge products. As a case in point, in January 2022, Paladin Labs Inc., a Canadian pharmaceutical company and a subsidiary of Endo International PLC, introduced Xydalba (dalbavancin for injection) in the Canadian market. Xydalba is an intravenous treatment designed for both adults and children aged three months and above, addressing acute bacterial skin and skin structure infections (ABSSSI). This second-generation semi-synthetic lipoglycopeptide antibiotic functions by disrupting the formation of bacterial cell walls, effectively eradicating the bacteria. It demonstrates effectiveness against numerous gram-positive bacteria, including the formidable methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI, denoting Acute Bacterial Skin and Skin Structure Infections, forms a specific subset of complicated skin and skin structure infections (cSSSI).

In March 2022, Cumberland Pharmaceuticals, a pharmaceutical firm based in the United States, joined forces with Tabuk Pharmaceuticals Manufacturing Company to create an innovative antibiotic with life-saving potential for the Middle East. This partnership marked the official launch of Cumberland's Vibativ (telavancin) injection in the Middle East. Vibativ stands as an advanced antibiotic developed to address complicated skin and skin structure infections (cSSIs) attributed to susceptible isolates of gram-positive bacteria. The collaboration entails the exclusive authorization for Tabuk to register and promote the product to patients across Saudi Arabia, Jordan, and potentially other nations in the Middle East. Tabuk Pharmaceuticals Manufacturing Company is a pharmaceutical enterprise headquartered in Saudi Arabia, specializing in the provision of pharmaceutical products within the Middle East and North America.

Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2024. The regions covered in complicated skin and skin structure infections drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

Complicated skin and skin structure infections (cSSSI) medications are a category of drugs designed to address a range of skin and soft tissue infections (SSTIs) affecting not only the skin but also deeper soft tissues like muscles, fascia, and subcutaneous tissues. These infections typically result from bacterial species and require effective management to prevent complications and enhance patient outcomes.

The primary active ingredients found in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline, fosamil, linezolid, and others. Delafloxacin, for instance, belongs to the fluoroquinolone antibiotic class, and it is employed for the treatment of skin and skin structure infections caused by specific bacteria. These drugs can be administered through various routes, including oral, topical, and parenteral, and they are utilized by a range of end users, such as hospitals, homecare services, specialty clinics, and others.

The complicated skin and skin structure infections drugs market research report is one of a series of new reports that provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.